Korro Bio, Inc. (KRRO)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$11.98-0.58%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Korro Bio, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	187,500
EPS	—	-1.349
Annual ending 2026-12-31
Revenue	—	333,333
EPS	—	-5.317
Annual ending 2027-12-31
Revenue	—	525,000
EPS	—	-4.883

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Extend cash runway into second half of 2028	It aims to extend cash runway into the second half of 2028.	Intact	Cash runway fails to extend into second half of 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated in 2 supplied transcript quarters. Cash, cash equivalents and marketable securities were $85.187 million at December 31, 2025 and $137.921 million at June 30, 2026; operating losses were $20.436 million in 2026-Q1 and $20.110 million in 2026-Q2. The stated runway into the second half of 2028 is supported by the reported cash balance and repeated runway estimate, though operating losses continue. Delivery assessment Oct 24, 2026
Reduce losses and improve earnings	A supporting condition in Korro Bio, Inc.'s published investment case. The stated target is EPS loss narrows to less than -$5.0 per share.	Improving	EPS loss worsens beyond -$5.0 per share in FY27	Diluted EPS: $-1.07 per share FY2026-Q2; GAAP. Published target: EPS loss narrows to less than -$5.0 per share. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-1.07 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 181f68bb-3073-4207-8b22-35b8c8a14801. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stabilize and improve revenue after steep decline	A primary condition in Korro Bio, Inc.'s published investment case. The stated target is Revenue decline less than 20% YoY.	Improving	Revenue decline exceeds 20% YoY in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-4.88

$-5.39 → $-4.88 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-5.39	$214,286	8 / 6
2026-07-25	$-5.39	$214,286	8 / 6
2026-07-26	$-5.39	$214,286	8 / 6
2026-07-27	$-5.39	$214,286	8 / 6
2026-07-28	$-5.39	$214,286	8 / 6
2026-07-29	$-5.04	$222,220	8 / 9
2026-07-30	$-5.04	$222,220	8 / 9
2026-07-31	$-5.04	$222,220	8 / 9
2026-08-01	$-5.39	$214,286	8 / 6
2026-08-02	$-5.39	$214,286	8 / 6
2026-08-03	$-5.04	$222,220	8 / 9
2026-08-04	$-5.04	$222,220	8 / 9
2026-08-05	$-5.04	$222,220	8 / 9
2026-08-06	$-5.39	$214,286	8 / 6
2026-08-07	$-5.32	$214,286	8 / 6
2026-08-08	$-4.67	$250,000	8 / 8
2026-08-09	$-4.67	$250,000	8 / 8
2026-08-10	$-5.32	$214,286	8 / 6
2026-08-12	$-5.32	$214,286	8 / 6
2026-08-13	$-5.32	$214,286	8 / 6
2026-08-14	$-5.32	$214,286	8 / 6
2026-08-15	$-5.32	$214,286	8 / 6
2026-08-16	$-5.32	$214,286	8 / 6
2026-08-17	$-5.32	$214,286	8 / 6
2026-08-18	$-5.32	$214,286	8 / 6
2026-08-19	$-5.32	$214,286	8 / 6
2026-08-20	$-4.89	$420,000	9 / 7
2026-08-21	$-4.89	$420,000	9 / 7
2026-08-22	$-4.89	$420,000	9 / 7
2026-08-23	$-4.89	$420,000	9 / 7
2026-08-24	$-4.89	$420,000	9 / 7
2026-08-25	$-4.89	$466,667	9 / 7
2026-08-26	$-4.89	$525,000	9 / 7
2026-08-27	$-4.89	$525,000	9 / 7
2026-08-28	$-4.89	$525,000	9 / 7
2026-08-29	$-4.89	$525,000	9 / 7
2026-08-30	$-4.89	$525,000	9 / 7
2026-08-31	$-4.89	$525,000	9 / 7
2026-09-01	$-4.89	$525,000	9 / 7
2026-09-02	$-4.89	$525,000	9 / 7
2026-09-03	$-4.89	$525,000	9 / 7
2026-09-04	$-4.89	$525,000	9 / 7
2026-09-05	$-4.89	$525,000	9 / 7
2026-09-06	$-4.88	$525,000	9 / 7
2026-09-07	$-4.88	$525,000	9 / 7
2026-09-08	$-4.88	$525,000	9 / 7
2026-09-09	$-4.88	$525,000	9 / 7
2026-09-10	$-4.88	$525,000	9 / 7
2026-09-11	$-4.88	$525,000	9 / 7
2026-09-12	$-4.88	$525,000	9 / 7
2026-09-13	$-4.88	$525,000	9 / 7
2026-09-14	$-4.88	$525,000	9 / 7
2026-09-15	$-4.88	$525,000	9 / 7
2026-09-16	$-4.88	$525,000	9 / 7
2026-09-17	$-4.88	$525,000	8 / 7
2026-09-18	$-4.88	$525,000	8 / 7
2026-09-19	$-4.88	$525,000	8 / 7
2026-09-20	$-4.88	$525,000	8 / 7
2026-09-21	$-4.88	$525,000	8 / 7
2026-09-22	$-4.88	$525,000	8 / 7
2026-09-23	$-4.88	$525,000	8 / 7
2026-09-24	$-4.88	$525,000	8 / 7
2026-09-25	$-4.88	$525,000	8 / 7
2026-09-26	$-4.88	$525,000	8 / 7
2026-09-27	$-4.88	$525,000	8 / 7
2026-09-28	$-4.88	$525,000	8 / 7
2026-09-29	$-4.88	$525,000	8 / 7
2026-09-30	$-4.88	$525,000	8 / 7
2026-10-01	$-4.88	$525,000	8 / 7
2026-10-02	$-4.88	$525,000	8 / 7
2026-10-03	$-4.88	$525,000	8 / 7
2026-10-04	$-4.88	$525,000	8 / 7
2026-10-05	$-4.88	$525,000	8 / 7
2026-10-06	$-4.88	$525,000	8 / 7
2026-10-07	$-4.88	$525,000	8 / 6
2026-10-08	$-4.88	$525,000	8 / 6
2026-10-09	$-4.88	$525,000	8 / 6
2026-10-10	$-4.88	$525,000	8 / 6
2026-10-11	$-4.88	$525,000	8 / 6
2026-10-12	$-4.88	$525,000	8 / 6
2026-10-13	$-4.88	$525,000	8 / 6
2026-10-14	$-4.88	$525,000	8 / 6
2026-10-15	$-4.88	$525,000	8 / 6
2026-10-16	$-4.88	$525,000	8 / 6
2026-10-17	$-4.88	$525,000	8 / 6
2026-10-18	$-4.88	$525,000	8 / 6
2026-10-19	$-4.88	$525,000	8 / 6
2026-10-20	$-4.88	$525,000	8 / 6
2026-10-21	$-4.88	$525,000	8 / 6
2026-10-22	$-4.88	$525,000	8 / 6
2026-10-23	$-4.88	$525,000	8 / 6
2026-10-24	$-4.88	$525,000	8 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	10	2
2026-06-01	10	1
2026-07-01	10	1
2026-08-01	10	1
2026-09-01	10	1
2026-10-01	10	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 10 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

JefferiesOct 6

$15.00New observation · no comparable prior

$0$8.25$16.50

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Extend cash runway into second half of 2028Direct metric needs a verified mapping
Reduce losses and improve earningsDiluted EPS: $-1.07 per share
Stabilize and improve revenue after steep declineDirect metric needs a verified mapping

Next proof point

Nov 11, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.7%Typical daily move · historical

Downside history

-87.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Korro Bio, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology company, not an established earnings compounder. The thesis is intact, with KRRO-121 advancing toward clinical testing and KRRO-111 still progressing before clinical delivery.

What's priced into Korro Bio, Inc.

The valuation evidence indicates a durable premium versus peers, while the expectations gap is marked unjustified. This suggests the premium is not clearly supported by the expectations measure in the snapshot, though confidence in that assessment is medium.

What the fundamentals likely do

Near term, continued operating losses and no reported clinical outcome data leave results dependent on execution rather than product revenue. Cash and marketable securities rose between year-end 2025 and June 2026, and management states the runway extends into the second half of 2028, but ongoing losses make that a point to monitor.

What Korro Bio, Inc. hinges on

The multi-year thesis hinges on advancing KRRO-121 into clinical testing and moving KRRO-111 from preclinical progress toward clinical delivery. Near term, a guidance cut would be a negative signal; weakening job growth could also weigh on healthcare names, while continued strength from sector bellwethers could support sector momentum.